Skip to main content
SpringerLink
Log in

Afatinib

Pneumonitis and respiratory failure: 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Choi C-M, et al. Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea. Translational Lung Cancer Research 10: 4353-4367, No. 12, Dec 2021. Available from: URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743522/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib. Reactions Weekly 1910, 18 (2022). https://doi.org/10.1007/s40278-022-16853-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-16853-0

Search

Navigation